PTC Therapeutics reported $-2.46M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 46.47M 42.49M Jun/2026
Alnylam Pharmaceuticals USD 177.81M 43.85M Jun/2026
Amgen USD 2.08B 570M Mar/2026
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
Biogen USD 647.3M 269.6M Jun/2026
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Cytokinetics USD -206.03M 23M Mar/2026
Daiichi Sankyo JPY -6.52B 113.25B Mar/2026
Enanta Pharmaceuticals USD -22.71M 95.08M Dec/2024
Gilead Sciences USD -7.53B 10.11B Jun/2026
Incyte USD 751.51M 407.91M Jun/2026
Ionis Pharmaceuticals USD -114M 21M Jun/2026
Ironwood Pharmaceuticals USD 68.02M 30.2M Sep/2025
Karyopharm Therapeutics USD -22.39M 17.51M Mar/2026
Novartis USD 4.27B 430M Jun/2026
Pfizer USD -653M 5.84B Jun/2026
PTC Therapeutics USD -2.46M 136.62M Mar/2026
Puma Biotechnology USD 20.61M 24.76M Sep/2024
Roche Holding CHF 11.17B 6.38B Jun/2026
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Sarepta Therapeutics USD -1.75M 344.92M Jun/2026
TG Therapeutics USD 10.23M 10.13M Jun/2026
Ultragenyx Pharmaceutical USD -91M 93M Jun/2026
Vertex Pharmaceuticals USD 1.39B 138.9M Jun/2026
Xencor USD -21.92M 106.72M Jun/2026